Quantifying delay in access to new medical treatment: An application of risk advancement period methodology

Karl J. Krobot, William C. Miller, Jay S. Kaufman, Dale B. Christensen, John S. Preisser, Michel Ibrahim

Research output: Contribution to journalArticle

Abstract

Background: We present a novel application of the concept of risk or rate advancement to compute the extent of delay in adoption of an effective new drug in 2 German health insurance systems. Methods: We identified individuals with migraines, age 18 to 65 years, in 371 primary care practices in Germany in 1994 (MediPlus, IMS Health database). These included 8173 persons covered under the statutory health insurance system and 503 persons covered by private health insurance. We derived risk and population risk advancement periods for sumatriptan compared with nonserotoninergic acute migraine therapy using multiplicative risk regression and generalized estimating equations, adjusted for patient, physician, and practice cofactors. Results: For patients at the mean age of the cohort, 43 years of age, sumatriptan was prescribed 1.2 (95% confidence interval [CI] = 0.3-2.0) years later among those in the statutory health insurance system compared with those who had private insurance. The lag increased by 0.6 (-0.1 to 1.3) years for every 10 years of patient age. In the age-mix of our sample, access to the health benefits of sumatriptan therapy lagged nearly 1.5 years behind in the statutory health insurance system and for Germany as a whole. Conclusions: Migraine patients' access to sumatriptan therapy lagged substantially in the statutory health insurance system and in the country as a whole. Risk advancement periods provide a useful methodology for communicating major healthcare issues in a meaningful way to society and policymakers.

Original languageEnglish (US)
Pages (from-to)202-207
Number of pages6
JournalEpidemiology
Volume15
Issue number2
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Health Insurance
Sumatriptan
Migraine Disorders
Germany
Therapeutics
Insurance Benefits
Insurance
Primary Health Care
Databases
Confidence Intervals
Delivery of Health Care
Physicians
Health
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Epidemiology

Cite this

Quantifying delay in access to new medical treatment : An application of risk advancement period methodology. / Krobot, Karl J.; Miller, William C.; Kaufman, Jay S.; Christensen, Dale B.; Preisser, John S.; Ibrahim, Michel.

In: Epidemiology, Vol. 15, No. 2, 03.2004, p. 202-207.

Research output: Contribution to journalArticle

Krobot, Karl J. ; Miller, William C. ; Kaufman, Jay S. ; Christensen, Dale B. ; Preisser, John S. ; Ibrahim, Michel. / Quantifying delay in access to new medical treatment : An application of risk advancement period methodology. In: Epidemiology. 2004 ; Vol. 15, No. 2. pp. 202-207.
@article{bdf983d6fc004604ad99e46b50e48b88,
title = "Quantifying delay in access to new medical treatment: An application of risk advancement period methodology",
abstract = "Background: We present a novel application of the concept of risk or rate advancement to compute the extent of delay in adoption of an effective new drug in 2 German health insurance systems. Methods: We identified individuals with migraines, age 18 to 65 years, in 371 primary care practices in Germany in 1994 (MediPlus, IMS Health database). These included 8173 persons covered under the statutory health insurance system and 503 persons covered by private health insurance. We derived risk and population risk advancement periods for sumatriptan compared with nonserotoninergic acute migraine therapy using multiplicative risk regression and generalized estimating equations, adjusted for patient, physician, and practice cofactors. Results: For patients at the mean age of the cohort, 43 years of age, sumatriptan was prescribed 1.2 (95{\%} confidence interval [CI] = 0.3-2.0) years later among those in the statutory health insurance system compared with those who had private insurance. The lag increased by 0.6 (-0.1 to 1.3) years for every 10 years of patient age. In the age-mix of our sample, access to the health benefits of sumatriptan therapy lagged nearly 1.5 years behind in the statutory health insurance system and for Germany as a whole. Conclusions: Migraine patients' access to sumatriptan therapy lagged substantially in the statutory health insurance system and in the country as a whole. Risk advancement periods provide a useful methodology for communicating major healthcare issues in a meaningful way to society and policymakers.",
author = "Krobot, {Karl J.} and Miller, {William C.} and Kaufman, {Jay S.} and Christensen, {Dale B.} and Preisser, {John S.} and Michel Ibrahim",
year = "2004",
month = "3",
doi = "10.1097/01.ede.0000112142.27474.ad",
language = "English (US)",
volume = "15",
pages = "202--207",
journal = "Epidemiology",
issn = "1044-3983",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Quantifying delay in access to new medical treatment

T2 - An application of risk advancement period methodology

AU - Krobot, Karl J.

AU - Miller, William C.

AU - Kaufman, Jay S.

AU - Christensen, Dale B.

AU - Preisser, John S.

AU - Ibrahim, Michel

PY - 2004/3

Y1 - 2004/3

N2 - Background: We present a novel application of the concept of risk or rate advancement to compute the extent of delay in adoption of an effective new drug in 2 German health insurance systems. Methods: We identified individuals with migraines, age 18 to 65 years, in 371 primary care practices in Germany in 1994 (MediPlus, IMS Health database). These included 8173 persons covered under the statutory health insurance system and 503 persons covered by private health insurance. We derived risk and population risk advancement periods for sumatriptan compared with nonserotoninergic acute migraine therapy using multiplicative risk regression and generalized estimating equations, adjusted for patient, physician, and practice cofactors. Results: For patients at the mean age of the cohort, 43 years of age, sumatriptan was prescribed 1.2 (95% confidence interval [CI] = 0.3-2.0) years later among those in the statutory health insurance system compared with those who had private insurance. The lag increased by 0.6 (-0.1 to 1.3) years for every 10 years of patient age. In the age-mix of our sample, access to the health benefits of sumatriptan therapy lagged nearly 1.5 years behind in the statutory health insurance system and for Germany as a whole. Conclusions: Migraine patients' access to sumatriptan therapy lagged substantially in the statutory health insurance system and in the country as a whole. Risk advancement periods provide a useful methodology for communicating major healthcare issues in a meaningful way to society and policymakers.

AB - Background: We present a novel application of the concept of risk or rate advancement to compute the extent of delay in adoption of an effective new drug in 2 German health insurance systems. Methods: We identified individuals with migraines, age 18 to 65 years, in 371 primary care practices in Germany in 1994 (MediPlus, IMS Health database). These included 8173 persons covered under the statutory health insurance system and 503 persons covered by private health insurance. We derived risk and population risk advancement periods for sumatriptan compared with nonserotoninergic acute migraine therapy using multiplicative risk regression and generalized estimating equations, adjusted for patient, physician, and practice cofactors. Results: For patients at the mean age of the cohort, 43 years of age, sumatriptan was prescribed 1.2 (95% confidence interval [CI] = 0.3-2.0) years later among those in the statutory health insurance system compared with those who had private insurance. The lag increased by 0.6 (-0.1 to 1.3) years for every 10 years of patient age. In the age-mix of our sample, access to the health benefits of sumatriptan therapy lagged nearly 1.5 years behind in the statutory health insurance system and for Germany as a whole. Conclusions: Migraine patients' access to sumatriptan therapy lagged substantially in the statutory health insurance system and in the country as a whole. Risk advancement periods provide a useful methodology for communicating major healthcare issues in a meaningful way to society and policymakers.

UR - http://www.scopus.com/inward/record.url?scp=2442442162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442442162&partnerID=8YFLogxK

U2 - 10.1097/01.ede.0000112142.27474.ad

DO - 10.1097/01.ede.0000112142.27474.ad

M3 - Article

C2 - 15127913

AN - SCOPUS:2442442162

VL - 15

SP - 202

EP - 207

JO - Epidemiology

JF - Epidemiology

SN - 1044-3983

IS - 2

ER -